Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Moberg Pharma

9.01 SEK

-1.04 %

Less than 1K followers

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.04 %
+15.60 %
+0.06 %
+0.39 %
-11.46 %
-44.00 %
-43.72 %
-76.21 %
-84.93 %

Moberg Pharma is a Swedish pharmaceutical company with a focus on commercialization of proprietary drugs based on proven substances. The company works primarily in nail fungus, where Moberg Pharma is developing a topical treatment. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among other places. The company's headquarters are located in Bromma.

Read more
Market cap
438.65M SEK
Turnover
109.85K SEK
Revenue
9.81M
EBIT %
-3,311.21 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/2
2026

Annual report '25

12/5
2026

Interim report Q1'26

21/5
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Press release11/14/2025, 11:32 AM

Redeye: Moberg Pharma (Q3 Review) - European footprint expanded, strengthening mid-/long-term outlook

Moberg Pharma
Regulatory press release11/11/2025, 7:00 AM

Moberg Pharmas delårsrapport januari - september 2025

Moberg Pharma
Regulatory press release11/11/2025, 7:00 AM

Moberg Pharma interim report January - September 2025

Moberg Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/6/2025, 10:15 AM

BioStock: Moberg Pharma kommenterar licensavtalet med Karo Healthcare

Moberg Pharma
Regulatory press release11/5/2025, 7:30 AM

Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential

Moberg Pharma
Regulatory press release11/5/2025, 7:30 AM

Moberg Pharma och Karo Healthcare ingår exklusivt licensavtal för MOB-015/Terclara i Europa, vilket driver tillväxt och marknadsexpansion

Moberg Pharma
Regulatory press release10/31/2025, 7:30 AM

Moberg Pharma's Nomination Committee appointed

Moberg Pharma
Regulatory press release10/31/2025, 7:30 AM

Moberg Pharmas valberedning utsedd

Moberg Pharma
Regulatory press release10/7/2025, 6:10 AM

Finansinspektionen: Flaggningsmeddelande i Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release9/29/2025, 12:00 PM

Bulletin from Moberg Pharma's Extraordinary General Meeting held on 29 September 2025

Moberg Pharma
Regulatory press release9/29/2025, 12:00 PM

Kommuniké från extra bolagsstämma i Moberg Pharma den 29 september 2025

Moberg Pharma
Regulatory press release9/3/2025, 6:00 AM

Notice of extraordinary general meeting in Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release9/3/2025, 6:00 AM

Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)

Moberg Pharma
Press release9/3/2025, 5:59 AM

Moberg Pharma utökar styrelsen och återkallar emissionsbemyndigande

Moberg Pharma
Press release9/3/2025, 5:59 AM

Moberg Pharma to Expand Board of Directors and Withdraw Share Issue Authorization

Moberg Pharma
Press release8/13/2025, 9:48 AM

Redeye: Moberg Pharma - Terclara is the market leader in both Sweden and Norway

Moberg Pharma
Regulatory press release8/12/2025, 6:00 AM

Moberg Pharma: Delårsrapport januari - juni 2025

Moberg Pharma
Regulatory press release8/12/2025, 6:00 AM

Moberg Pharma: Interim report January - June 2025

Moberg Pharma
Regulatory press release7/3/2025, 2:30 PM

Finansinspektionen: Flaggningsmeddelande i Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release7/3/2025, 8:31 AM

Finansinspektionen: Flaggningsmeddelande i Moberg Pharma AB (publ)

Moberg Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.